Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: Two year results from the RIO-Europe Study

European Heart Journal

Volumn 29, Issue 14, 2008, Pages 1761-1771

  Van Gaal, Luc F ^a   Scheen, André J ^b   Rissanen, Aila M ^c   Rössner, Stephan ^d   Hanotin, Corinne ^e   Ziegler, Olivier ^f  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SANOFI   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Cardiovascular risk factors; CB1 receptor; Endocannabinoid system; Obesity; Overweight; Rimonabant

Indexed keywords

CANNABINOID 1 RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EUROPE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INFLUENZA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POLYP; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT LOSS;

EID: 42449136138     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn076     Document Type: Article

References (34)

1. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-2967.
2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.
4. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galieque S, Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19:1567- 1569.
5. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-589.
6. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
7. 1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005;29:183-187.
8. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
9. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-R353.
10. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst ACE, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
11. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005;83:944-954.
12. 2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 2006;39:155-162.
13. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
14. Matias I, Gonthier M-P, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180.
15. Sipe J, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 2005;29:755-759.
16. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
17. Després JP, Golay A, Sjöström L, for the Rimonabant in Obesity-Lipids Study Group. Effect of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121- 2134.
18. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775.
19. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006;368:1660-1672.
20. Van Gaal LF, Wauters MA, de Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(Suppl. 1):S5-S9.
21. Jacobs D, Demott WR, Grady HJ, Horvat RT, Huestis DW, Kasten Jr BJ. Laboratory Test Handbook. 4th ed. Hudson: Lexi-Comp; 1996.
22. NCEP ATP III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106:3143-3421.
23. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
25. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care 1992;30:473-483.
26. Kolotkin RL, Head S, Brookhart A. Construct validity of the Impact of Weight on Quality of Life Questionnaire. Obes Res 1997;5:434-441.
27. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
28. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802.
29. Wadden TA, Frey DL. A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up. Int J Eat Disord 1997;22:201-212.
30. Lowe MR, Miller-Kovach K, Phelan S. Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight-loss program. Int J Obes Relat Metab Disord 2001;25:325- 331.
31. Deedwania PC, Fonseca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005;118:939-947.
32. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-1713.
33. Sanofi-aventis. Acomplia: European Public Assessment Report. Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/ H-666-PI-en.pdf (21 November 2007).
34. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol 1992;70:733-777.